Opinion|Videos|October 21, 2024
Factors Impacting Use of HER2 Therapies for NSCLC
Key Takeaways
- Barriers to HER2-directed therapies include high costs, limited insurance coverage, and stringent prior authorization requirements, impacting patient access and treatment initiation.
- Providers prioritize clinical outcomes like progression-free survival and overall response rates, which may not align with payer focus on cost-effectiveness.
Panelists discuss how payer perspectives and access challenges impact the utilization of HER2-directed therapies in NSCLC, examining barriers to treatment initiation and persistence, aligning provider and payer priorities in outcome assessment, the role of real-world evidence in decision-making and policy formation, and strategies for collaborative efforts between stakeholders to balance equitable access with cost management.
Advertisement
Episodes in this series
Video content above is prompted by the following:
Analyze payer perspectives and access challenges related to HER2-directed therapies in NSCLC.
- (Kim) What are potential barriers to starting and/or persisting on HER2-directed therapies for NSCLC?
- (Bazhenova) Which outcomes do providers find most important in clinical practice, and how do these align with the outcomes payers prioritize when assessing the value of these therapies?
Advertisement
Related to this article
A systematic review and meta-analysis found GLP-1 RAs improved liver and metabolic markers in MASLD and MASH, but long-term benefits remain unproven.
Mailed fecal immunochemical test (FIT) outreach raised CRC screening at federally qualified health centers, but gains faded by year 3.
SIRVA was rare after COVID-19 and flu shots, but COVID-19 vaccination had about 7 more cases per 100,000 doses in a study of 1.8 million.
Mucus plugs on chest CT may signal higher COPD hospitalization and death risk even without cough, and early data suggest they can be treated.
Antimicrobial resistance in bronchiectasis and cystic fibrosis varied widely in a study spanning 11 centers on 3 continents.
Experts break down the GOLD 2026 COPD guidelines, highlighting updates to diagnosis criteria, Group E risk categories, and nonpharmacologic interventions.
An economic evaluation found nontargeted hepatitis C screening in emergency departments offered the greatest health benefit at a cost-effective price.
Advertisement
Advertisement
Trending on AJMC
1
Hepatitis B Functional Cure Persists Off Treatment After Bepirovirsen
2
Health Equity & Access Weekly Roundup: November 6, 2026
3
Medicaid Cuts and Caregiving in Congress: Andy Kim
4
COPD’s Old Narrative Is Outdated, GOLD Leaders Say in 2027 Update
5